Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering Corp IMRX
$4.13
▼ -2.36%
($-0.10)
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$4.28
Prev Close
$4.23
Day Range
$4.06 – $4.28
52W Range
$2.90 – $10.08
Market Cap
$267.20M
Beta
0.27
EPS (TTM)
$-1.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-07-30 |
| Shares Out. | 64,700,000 |
| Website | immuneering.com/ ↗ |
| Phone | 16175008080 |
| Employees | 55 |
| Net Income | -$13.5M |
| Free Cash Flow | -$49.9M |
| Total Assets | $214.8M |
| Total Liabilities | $8.3M |
| Equity | $206.5M |
About Immuneering Corp
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Immuneering Corp is a publicly traded company under the ticker symbol IMRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)
📰 Latest News for IMRX
Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors
Needham Maintains Buy on Immuneering, Raises Price Target to $18